{
  "schema_version": "5.0",
  "artifact_kind": "company_profile",
  "language": "zh-CN",
  "generated_on": "2026-11-11",
  "research_as_of": "2026-11-10",
  "input_context": {
    "name_zh": "康龙化成",
    "name_en": "Pharmaron",
    "industry_level1": "医药健康",
    "industry_level2": "",
    "official_website": "www.pharmaron.com",
    "company_type": "品牌方",
    "logo_url": "https://cdn.brandfetch.io/domain/www.pharmaron.com/w/256/h/256/fallback/lettermark/type/icon?c=1idH6DEOXL4sEn7V6hN"
  },
  "entity": {
    "name_zh": "康龙化成（北京）新药技术股份有限公司",
    "scope": "上市主体300759.SZ/03759.HK及财报合并子公司；Pharmaron统一研发服务品牌，Biortus与海心智惠等按受控平台角色列示，PharmaGend为参股合作。",
    "source_ids": [
      "S01",
      "S02",
      "S04"
    ]
  },
  "basic_info": [
    {
      "key": "legal_name",
      "label": "法定主体或所属主体",
      "value": "康龙化成（北京）新药技术股份有限公司（Pharmaron Beijing Co., Ltd.）",
      "source_ids": [
        "S01",
        "S02"
      ]
    },
    {
      "key": "founded",
      "label": "成立时间",
      "value": "2004年7月",
      "source_ids": [
        "S01"
      ]
    },
    {
      "key": "headquarters",
      "label": "总部",
      "value": "中国北京市北京经济技术开发区泰河路6号；注册及年报总部地址为1幢八层",
      "source_ids": [
        "S01"
      ]
    },
    {
      "key": "listing",
      "label": "上市情况",
      "value": "深交所创业板300759及香港联交所H股03759，A+H上市",
      "source_ids": [
        "S01",
        "S04"
      ]
    },
    {
      "key": "employees",
      "label": "员工人数",
      "value": 27316,
      "unit": "人",
      "as_of": "2026-06-30",
      "scope": "2026中报集团员工总人数27316，研发、生产技术及临床服务24953为其中子集；不把子集当总人数，不与2025年底25088相加",
      "source_ids": [
        "S02"
      ],
      "display": "27,316人"
    },
    {
      "key": "revenue",
      "label": "营业收入",
      "value": 14095078734.95,
      "unit": "CNY",
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "basis": "calendar_year"
      },
      "scope": "2025完整自然年中国企业会计准则合并营业收入，含21902233.22元其他业务，不取仅主营14073176501.73",
      "source_ids": [
        "S01"
      ],
      "display": "140.95亿元人民币"
    },
    {
      "key": "current_year_revenue",
      "label": "今年营业收入",
      "value": 12003359881.83,
      "unit": "CNY",
      "period": {
        "start": "2026-01-01",
        "end": "2026-09-30",
        "basis": "calendar_year"
      },
      "scope": "2026年前三季度未经审计合并累计收入；香港10月27日原始公告已披露，A股归档及签署28日；不用单季4407936060.32元或15%-20%全年预期",
      "statement_date": "2026-10-27",
      "source_ids": [
        "S03",
        "S04"
      ],
      "display": "120.03亿元人民币"
    },
    {
      "key": "international_revenue",
      "label": "国际业务收入",
      "value": 11957897111.72,
      "unit": "CNY",
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "basis": "calendar_year"
      },
      "scope": "2025营业收入构成按客户所在地区列“国外”的全部营业收入，包括国外其他业务；不取仅主营11956086466.48元或海外子公司交付174908.07万元，不自行重划港澳台",
      "source_ids": [
        "S01"
      ],
      "display": "119.58亿元人民币"
    },
    {
      "key": "international_revenue_share",
      "label": "国际收入占比",
      "value": 84.84,
      "unit": "%",
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "basis": "calendar_year"
      },
      "scope": "2025年报直接披露国外全部营业收入11957897111.72占同期合并14095078734.95的84.84%；不混用海外设施交付占比12.41%",
      "source_ids": [
        "S01"
      ],
      "display": "84.84%"
    },
    {
      "key": "sales_coverage",
      "label": "销售覆盖国家及地区",
      "value": "-",
      "source_ids": [],
      "display": "-"
    }
  ],
  "overview": {
    "paragraphs": [
      {
        "text": "康龙化成为药企、生命科技及医疗器械客户提供贯穿药物发现、临床前、临床与商业化的CRO/CDMO服务，覆盖小分子、大分子、ADC及细胞与基因治疗。合同制生产和研究交付为主，客户在研药物不列作康龙自有获批药品。",
        "source_ids": [
          "S01",
          "S02",
          "S05"
        ]
      },
      {
        "text": "2025年合并收入140.95亿元，其中国外客户收入119.58亿元，占84.84%；海外子公司交付收入另为17.49亿元。2026年前三季度累计收入120.03亿元，最新明确期末集团员工为2026年6月底27,316人。",
        "source_ids": [
          "S01",
          "S02",
          "S03",
          "S04"
        ]
      }
    ]
  },
  "business": {
    "paragraphs": [
      {
        "text": "业务交付包含实验室化学、结构生物学、体内外药理、DMPK、安全评价与生物分析；小分子工艺开发、原料药及制剂GMP定制生产；大分子、抗体偶联物与基因治疗工艺和GMP生产；国内外临床试验及现场管理、注册与数据统计。按实质服务归类，不把客户疗法、疾病适应症或每项分析方法各当一种自有药品。",
        "source_ids": [
          "S01",
          "S02",
          "S05",
          "S08"
        ]
      },
      {
        "text": "佰翱得Biortus为受控结构生物学及蛋白平台。除定制研究，Biortus USA确有可订购重组蛋白目录，以及独立试剂和检测套装，必须与CRO服务分开。CDK、DUB、激酶及膜蛋白为蛋白商品系列；官网在线付款暂关，仍提供直接联系及目录，不误写网上结账正常。",
        "source_ids": [
          "S01",
          "S02",
          "S14",
          "S15",
          "S16"
        ]
      },
      {
        "text": "康龙临床与联斯达、康斯达按临床/现场及患者管理实际分工说明，海心智惠拥有海心健康、海心医生及CSCO AI辅助决策软件，并开展院内外患者管理与真实世界研究服务。2026年2月重组后公司直接持海心智惠70.44%，康斯达归海心智惠100%持有；不沿用2025年间接42.31%口径。",
        "source_ids": [
          "S01",
          "S02",
          "S09",
          "S10",
          "S11",
          "S12"
        ]
      },
      {
        "text": "RadioTag是放射性蛋白标记方法，不是另一个药物品牌或独立治疗药品。海心App下载软件与患者在线服务分别记录，普通研究门户及内部AI工具不推定开放商业API。量子计算及具身机器人合作尚处探索，不表示康龙制造销售通用机器人或量子计算机。新加坡PharmaGend为参股制剂合作，不并作受控品牌。",
        "source_ids": [
          "S02",
          "S03",
          "S05",
          "S08"
        ]
      }
    ],
    "brands": [
      {
        "name": "Pharmaron 康龙化成",
        "description": "集团统一CRO/CDMO服务品牌；客户药品、器械和研究项目归客户，集团实验室/工厂及RadioTag方法按实际交付列服务。",
        "source_ids": [
          "S01",
          "S02",
          "S05"
        ],
        "website": "https://www.pharmaron.com/",
        "industries": [
          {
            "level1": "医药健康",
            "level2": "CRO/CDMO"
          }
        ],
        "products": [],
        "services": [
          {
            "name": "药物发现与临床前实验室研发",
            "description": "实验室化学及药物设计、DEL与合成、结构生物学、体内外药理、DMPK/ADME、安全评价、生物分析及医疗器械检测，为客户交付实验材料、研究数据与报告；小分子、多肽、核酸、ADC及蛋白降解剂属于对象或技术，不各设自有药品。",
            "source_ids": [
              "S01",
              "S02",
              "S05"
            ],
            "website": "https://www.pharmaron.com/"
          },
          {
            "name": "小分子原料药与制剂CDMO",
            "description": "工艺开发放大、晶型及材料科学、分析和质控、临床及商业GMP原料药与制剂生产，按客户定制和合同制造交付；不将客户口服GLP-1候选药变为康龙自有药品。",
            "source_ids": [
              "S01",
              "S02"
            ],
            "website": "https://www.pharmaron.com/"
          },
          {
            "name": "大分子、ADC及基因治疗研发生产",
            "description": "细胞株、上下游工艺、抗体/连接子/弹头及偶联、质粒与病毒载体开发生产、产品鉴定、GMP放行和法规支持；中国宁波及英国利物浦设施分工有据。",
            "source_ids": [
              "S01",
              "S02",
              "S05"
            ],
            "website": "https://www.pharmaron.com/"
          },
          {
            "name": "放射性标记与临床转化研究",
            "description": "碳14/氚合成、GMP标记API/IMP、人体ADME、AMS高灵敏分析及RadioTag蛋白标记，交付定制标记材料与研究数据；不把放射性研究误写放射治疗药销售。",
            "source_ids": [
              "S01",
              "S02",
              "S08"
            ],
            "website": "https://www.pharmaron.com/services/clinical-development/integrated-radiolabelled-sciences/radiolabelling-and-radiosynthesis/tritium-and-carbon-14-radiolabels-radiotag-2/"
          },
          {
            "name": "美国早期临床与临床分析",
            "description": "马里兰州96床独立早期临床中心，提供首次人体、疫苗/感染挑战、跨种族桥接、TQT、生物分析、临床运营与注册等机构客户研发服务。",
            "source_ids": [
              "S02",
              "S06"
            ],
            "website": "https://www.pharmaron.com/"
          }
        ]
      },
      {
        "name": "康龙临床",
        "description": "集团受控国内临床研发平台，联斯达作为旗下现场管理品牌另列；康斯达2026年2月重组至海心智惠，按患者相关交付说明。",
        "source_ids": [
          "S01",
          "S02"
        ],
        "website": "https://www.pharmaron.com/",
        "industries": [
          {
            "level1": "医药健康",
            "level2": "临床研究"
          }
        ],
        "products": [],
        "services": [
          {
            "name": "全流程临床开发",
            "description": "I—IV期临床开发、医学/注册/运营、生物统计与数据管理、药物警戒、生物分析及定量药理，面向药企和研发机构交付临床研究。",
            "source_ids": [
              "S01",
              "S02"
            ],
            "website": "https://www.pharmaron.com/"
          }
        ]
      },
      {
        "name": "联斯达",
        "description": "康龙临床体系内的受控临床研究现场管理品牌，与集团CRO平台和海心患者管理分工说明。",
        "source_ids": [
          "S01",
          "S02"
        ],
        "website": "https://www.linkstart.com.cn/",
        "industries": [
          {
            "level1": "医药健康",
            "level2": "临床研究现场管理"
          }
        ],
        "products": [],
        "services": [
          {
            "name": "临床研究现场管理（SMO）",
            "description": "为药械研发客户和研究机构提供CRC、临床研究中心快速启动、受试者招募与管理、质量保障等现场执行服务。",
            "source_ids": [
              "S01",
              "S02"
            ],
            "website": "https://www.linkstart.com.cn/"
          }
        ]
      },
      {
        "name": "Biortus 佰翱得 / Biortus USA",
        "description": "2025收购协议及2026中报列82.54%受控结构生物学平台；当前官网使用全资描述但未标股权变化完成时间，不据此覆盖截至期末披露比例。美国平台兼营现货蛋白商品。",
        "source_ids": [
          "S01",
          "S02",
          "S07",
          "S14",
          "S15"
        ],
        "website": "https://www.biortus.bio/en/about.html",
        "industries": [
          {
            "level1": "医药健康",
            "level2": "结构生物学及研究试剂"
          }
        ],
        "products": [
          {
            "category": "研究用重组蛋白",
            "series": [],
            "representative_products": [
              {
                "name": "CDK/激酶蛋白",
                "website": null
              },
              {
                "name": "膜蛋白与蛋白降解相关蛋白",
                "website": null
              }
            ],
            "description": "现货及定制靶点重组蛋白，涵盖CDK、DUB、UPS/E1-E2-E3、激酶、Ras、GPCR/SLC膜蛋白、蛋白酶及其他研究蛋白；系列不因靶点各设主类。",
            "source_ids": [
              "S15",
              "S16"
            ],
            "website": "https://biortususa.com/products"
          },
          {
            "category": "研究试剂与检测套装",
            "series": [],
            "representative_products": [
              {
                "name": "DUB Inhibitor Screening Kits",
                "website": null
              },
              {
                "name": "Cell-free Protein Synthesis Kits",
                "website": null
              }
            ],
            "description": "官网单列DUB抑制剂筛选试剂盒、无细胞蛋白合成试剂盒以及其他检测用试剂套装；不隐藏于蛋白商品，未作为患者药物。",
            "source_ids": [
              "S16"
            ],
            "website": "https://biortususa.com/products"
          }
        ],
        "services": [
          {
            "name": "蛋白与结构驱动药物发现研究",
            "description": "从基因、蛋白生产纯化到测定筛选、NMR、X射线晶体学和冷冻电镜结构解析，AI/ML辅助蛋白设计与实验验证，为药物发现交付实验数据与定制蛋白。",
            "source_ids": [
              "S07",
              "S14"
            ],
            "website": "https://www.biortus.bio/en/about.html"
          }
        ]
      },
      {
        "name": "海心智惠（海心健康、海心医生、CSCO AI）",
        "description": "受控数字健康与患者管理平台；2026年2月重组后集团直接持70.44%，康斯达为海心智惠全资子公司；CSCO为学会合作方，不能声称拥有整个学会品牌。",
        "source_ids": [
          "S02",
          "S09",
          "S10",
          "S11",
          "S12"
        ],
        "website": "https://www.aistarfish.com/",
        "industries": [
          {
            "level1": "医药健康",
            "level2": "患者管理及数字医疗"
          }
        ],
        "products": [
          {
            "category": "医患应用及辅助决策软件",
            "series": [],
            "representative_products": [
              {
                "name": "海心健康App",
                "website": null
              },
              {
                "name": "海心医生App",
                "website": null
              },
              {
                "name": "CSCO AI辅助诊疗系统",
                "website": null
              }
            ],
            "description": "海心健康患者App含计划提醒、指标/不良反应监测、病友社区与临床研究匹配；海心医生App及CSCO AI辅助医生决策、患者可视化与医疗工作流程，软件不代表具备自主诊疗替代医师的能力。",
            "source_ids": [
              "S09",
              "S10",
              "S11",
              "S12"
            ],
            "website": "https://www.aistarfish.com/"
          }
        ],
        "services": [
          {
            "name": "患者全病程管理及真实世界研究",
            "description": "为医疗机构、患者及研发机构提供院内外患者管理、随访监测、数据整理和真实世界研究相关服务，中报披露相关订单初具规模。具体医疗行为由合规机构与医师履行，不推定集团所有CRO均向公众诊疗。",
            "source_ids": [
              "S02",
              "S09",
              "S10",
              "S11"
            ],
            "website": "https://www.aistarfish.com/"
          }
        ]
      },
      {
        "name": "PharmaGend（参股合作平台）",
        "description": "新加坡后期及商业化制剂CDMO参股企业；中报明确作为国际服务合作部署，官网全球设施虽列Singapore，不据此认作全资合并工厂。",
        "source_ids": [
          "S01",
          "S02",
          "S06"
        ],
        "website": "https://www.pharmaron.com/about-us/locations/",
        "industries": [
          {
            "level1": "医药健康",
            "level2": "制剂CDMO合作"
          }
        ],
        "products": [],
        "services": []
      }
    ],
    "services": []
  },
  "global_presence": {
    "paragraphs": [
      {
        "text": "2025年按客户所在地的收入主要来自北美61.82%、欧洲含英国20.54%，另有中国15.16%及其他地区2.48%；国外全部营业收入84.84%。海外子公司交付收入12.41%是生产/服务交付地，不是海外客户收入，二者不能混写。未取得净境外客户国家数。",
        "source_ids": [
          "S01"
        ]
      },
      {
        "text": "2026中报列中国、英国、美国和新加坡共28个运营实体（海外12个），其中新加坡由参股PharmaGend拓展制剂服务，不能将28个全部解释为受控工厂。自营实物设施以中国总部和各园区、英国Hoddesdon/Rushden/Cardiff/Cramlington/Liverpool，以及美国Coventry、Baltimore、San Diego、Germantown、Boston和Exton等实验室/生产/临床地点为证。",
        "source_ids": [
          "S02",
          "S06"
        ]
      },
      {
        "text": "具体境外市场仅列有当地实质研发生产服务供给支持的英国、美国及新加坡参股合作；全球客户地区汇总不足以列出其他国家。中国新建杭州钱塘基地和绍兴第二园区为投资建设计划，不能将设计产能视为已投产。",
        "source_ids": [
          "S02",
          "S03",
          "S06"
        ]
      }
    ],
    "market_regions": [
      {
        "region": "亚洲",
        "countries": [
          "新加坡"
        ],
        "source_ids": [
          "S01",
          "S02",
          "S06"
        ]
      },
      {
        "region": "欧洲",
        "countries": [
          "英国"
        ],
        "source_ids": [
          "S01",
          "S02",
          "S06"
        ]
      },
      {
        "region": "非洲",
        "countries": [
          "-"
        ],
        "source_ids": []
      },
      {
        "region": "北美洲",
        "countries": [
          "美国"
        ],
        "source_ids": [
          "S01",
          "S02",
          "S06"
        ]
      },
      {
        "region": "南美洲",
        "countries": [
          "-"
        ],
        "source_ids": []
      },
      {
        "region": "大洋洲",
        "countries": [
          "-"
        ],
        "source_ids": []
      }
    ],
    "operating_regions": [
      {
        "region": "亚洲",
        "countries": [
          "中国"
        ],
        "source_ids": [
          "S02",
          "S06"
        ]
      },
      {
        "region": "欧洲",
        "countries": [
          "英国"
        ],
        "source_ids": [
          "S02",
          "S06"
        ]
      },
      {
        "region": "非洲",
        "countries": [
          "-"
        ],
        "source_ids": []
      },
      {
        "region": "北美洲",
        "countries": [
          "美国"
        ],
        "source_ids": [
          "S02",
          "S06"
        ]
      },
      {
        "region": "南美洲",
        "countries": [
          "-"
        ],
        "source_ids": []
      },
      {
        "region": "大洋洲",
        "countries": [
          "-"
        ],
        "source_ids": []
      }
    ]
  },
  "developments": {
    "window": {
      "start": "2025-11-10",
      "end": "2026-11-10",
      "max_items": 5
    },
    "items": [
      {
        "id": "E01",
        "title": "康龙英国签署境外生物医药基金认购",
        "importance": "major",
        "display_date": "2026-11-06",
        "summary": "全资英国子公司签署HJ Double Helix Fund有限合伙认购文件，认缴1000万美元；认缴不等于已全额支付或已实现收益。",
        "status": "completed_per_company_statement",
        "source_ids": [
          "S17"
        ]
      },
      {
        "id": "E02",
        "title": "完成境外零息可转债发行披露",
        "importance": "major",
        "display_date": "2026-10-27",
        "summary": "第三季度报告披露2026年9月发行人民币21.80亿元、2027年到期的美元结算零息可转债，约七成净款拟用于实验室及CDMO扩张；引用9月2日完成公告。",
        "status": "completed_per_company_statement",
        "source_ids": [
          "S03",
          "S04"
        ]
      },
      {
        "id": "E03",
        "title": "计划建设杭州与绍兴新增CDMO基地",
        "importance": "major",
        "display_date": "2026-08-21",
        "summary": "中报披露5月批准杭州钱塘约20亿元基地及绍兴第二园区约30亿元、200吨医药中间体及API项目；实际总投资以最终为准。",
        "status": "announced",
        "source_ids": [
          "S02"
        ]
      },
      {
        "id": "E04",
        "title": "达成口服小分子GLP-1制剂商业化合作",
        "importance": "major",
        "display_date": "2026-08-21",
        "summary": "中报确认3月与未在该报告中具名的国际大型药企达成其首个申报注册口服小分子GLP-1受体激动剂的制剂商业化生产合作。",
        "status": "completed_per_company_statement",
        "source_ids": [
          "S02"
        ]
      },
      {
        "id": "E05",
        "title": "完成新H股配售",
        "importance": "major",
        "display_date": "2026-01-22",
        "summary": "向不少于六名独立承配人配售58440762股H股，净募集约人民币11.85亿元，投向项目建设、还贷及营运。",
        "status": "completed_per_company_statement",
        "source_ids": [
          "S02"
        ]
      }
    ]
  },
  "sources": [
    {
      "id": "S01",
      "title": "康龙化成2025年度报告（发行人原报镜像）",
      "url": "https://file.finance.sina.com.cn/211.154.219.97:9494/MRGG/CNSESZ_STOCK/2026/2026-3/2026-03-31/12042867.PDF",
      "type": "official_report",
      "accessed_on": "2026-11-11",
      "published_at": "2026-03-31"
    },
    {
      "id": "S02",
      "title": "康龙化成2026半年度报告",
      "url": "https://static.cninfo.com.cn/finalpage/2026-08-21/1225487380.PDF",
      "type": "official_report",
      "accessed_on": "2026-11-11",
      "published_at": "2026-08-21"
    },
    {
      "id": "S03",
      "title": "康龙化成2026第三季度报告A股原报",
      "url": "https://static.cninfo.com.cn/finalpage/2026-10-28/1225629302.PDF",
      "type": "official_report",
      "accessed_on": "2026-11-11",
      "published_at": "2026-10-28"
    },
    {
      "id": "S04",
      "title": "港交所2026第三季度报告首次披露",
      "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1027/2026102700966_c.pdf",
      "type": "regulatory",
      "accessed_on": "2026-11-11",
      "published_at": "2026-10-27"
    },
    {
      "id": "S05",
      "title": "Pharmaron服务及多疗法总目录",
      "url": "https://www.pharmaron.com/",
      "type": "official",
      "accessed_on": "2026-11-11"
    },
    {
      "id": "S06",
      "title": "Pharmaron全球实际服务设施目录",
      "url": "https://www.pharmaron.com/about-us/locations/",
      "type": "official",
      "accessed_on": "2026-11-11"
    },
    {
      "id": "S07",
      "title": "Pharmaron收购Biortus82.54%协议",
      "url": "https://www.pharmaron.com/about-us/latest-news/pharmaron-acquires-biortus/",
      "type": "official_news",
      "accessed_on": "2026-11-11",
      "published_at": "2025-10-28"
    },
    {
      "id": "S08",
      "title": "RadioTag放射性标记方法及研发服务",
      "url": "https://www.pharmaron.com/services/clinical-development/integrated-radiolabelled-sciences/radiolabelling-and-radiosynthesis/tritium-and-carbon-14-radiolabels-radiotag-2/",
      "type": "official",
      "accessed_on": "2026-11-11"
    },
    {
      "id": "S09",
      "title": "海心健康官网与应用下载",
      "url": "https://www.aistarfish.com/",
      "type": "official",
      "accessed_on": "2026-11-11"
    },
    {
      "id": "S10",
      "title": "海心患者应用及管理功能",
      "url": "https://www.aistarfish.com/patientdesc",
      "type": "official",
      "accessed_on": "2026-11-11"
    },
    {
      "id": "S11",
      "title": "海心医生与CSCO AI系统",
      "url": "https://www.aistarfish.com/doctordesc",
      "type": "official",
      "accessed_on": "2026-11-11"
    },
    {
      "id": "S12",
      "title": "海心医生隐私协议2.5.2及运营主体",
      "url": "https://static.aistarfish.com/front-release/html/F2021071417133148500000019.deploy.html",
      "type": "official",
      "accessed_on": "2026-11-11",
      "published_at": "2026-08-27"
    },
    {
      "id": "S13",
      "title": "海心商城公开页",
      "url": "https://www.aistarfish.com/mall",
      "type": "official",
      "accessed_on": "2026-11-11"
    },
    {
      "id": "S14",
      "title": "Biortus结构生物学服务及集团关系说明",
      "url": "https://www.biortus.bio/en/about.html",
      "type": "official",
      "accessed_on": "2026-11-11"
    },
    {
      "id": "S15",
      "title": "Biortus USA蛋白目录总览",
      "url": "https://biortususa.com/",
      "type": "official",
      "accessed_on": "2026-11-11"
    },
    {
      "id": "S16",
      "title": "Biortus USA蛋白、试剂与检测套装目录",
      "url": "https://biortususa.com/products",
      "type": "official",
      "accessed_on": "2026-11-11"
    },
    {
      "id": "S17",
      "title": "康龙英国参与HJ Double Helix基金公告原文",
      "url": "https://file.finance.sina.com.cn/211.154.219.97:9494/MRGG/CNSESZ_STOCK/2026/2026-11/2026-11-06/12695742.PDF",
      "type": "official_report",
      "accessed_on": "2026-11-11",
      "published_at": "2026-11-06"
    }
  ],
  "report_template": "core-v4"
}
